Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Atopic dermatitis

Systemic therapy in transition

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • RX
  • 4 minute read

Until now, systemic treatment of atopic dermatitis has been overshadowed by side effect risks. Dupilumab, a biologic that has proven to be highly effective and safe, has been available as an alternative for adults with moderate to severe atopic dermatitis since last year. The market approval of this monoclonal antibody has significantly changed the therapeutic spectrum for this indication.

In contrast to conventional systemic therapy options, biologics very specifically influence certain cellular processes, thereby reducing the risk of side effects. Dupilumab is the first biologic that effectively modifies the pathophysiology of Th2-mediated allergic diseases and has a good safety profile [1]. Until the market approval of this monoclonal antibody, systemic therapies for moderate to severe atopic dermatitis were limited to oral glucocorticoids, ciclosporin, and off-label substances (e.g., azathioprine, mycophenolate mofetil, methotrexate) [2]. Oral glucocorticoids show a marked effect, but longer-term treatment is not recommended due to risks of side effects (e.g., skin and muscle atrophy, osteoporosis, increase in blood glucose levels). Ciclosporin dampens the immune response and thus also inhibits the inflammatory process. This active ingredient can also lead to undesirable side effects when taken over a longer period of time (e.g., impairment of kidney function). Off-label therapeutics (e.g., azathioprine, mycophenolate mofetil, methotrexate) are used in adults in some cases when other treatment is not effective due to inadequate response or side effects.

 

 

Th2 cell-mediated processes as a therapeutic target of dupilumab.

By intervening in the disease process in a very targeted manner, the risk of side effects is reduced. Since biologics cannot be absorbed by the mucosa of the gastrointestinal tract due to their structure, they are not taken in tablet form but injected subcutaneously. Dupilumab (Dupixent®) [3] is available as a pre-filled syringe in the prescribed dosage and can be self-administered by patients after medical instruction. The compound, produced by recombinant DNA technology from Chinese hamster ovary cells, is a human IgG4 monoclonal antibody that binds to the alpha subunit of the IL4 receptor, inhibiting IL4/IL13 signaling pathways [4]. This downregulation of Th2-mediated inflammatory processes makes dupilumab effective in various allergic diseases [5]. Type 2 helper (Th2)-cell mediated immune responses play an important role in the pathogenesis of atopic dermatitis by secreting excessive amounts of IL4 and IL13. These two cytokines stimulate the formation of IgE antibodies, resulting in an inflammatory defense response to the irritants. As a result, a vicious circle of disturbed skin barrier, penetration of irritants, inflammation, unbearable itching and scratching and further damage to the skin can develop. Very severe damage to the skin can lead to chronic inflammation (overview 1) and there may be a secondary reduction in barrier function due to inflammation, which phase-dependently involves an interaction between keratinocytes, dendritic cells, cutaneous mast cells, and T cells with corresponding proinflammatory cytokines [2]. At the molecular level, dupilumab led to a reduction in the signature of over 800 genes involved in atopic dermatitis, including those for Th2 chemokines, T cell proliferation, and dendritic cells [6]. Research into the various cellular targets of dupilumab is ongoing [1].

 

 

Severity-adapted treatment

Atopic dermatitis is based on a multifactorial pathogenesis [7]: There are genetic predispositions regarding a disturbance of the epidermal barrier function and of already mentioned complex dysregulations of the immune system with a tendency to develop IgE-mediated sensitizations. (Fig.1). Exogenous trigger factors include irritant substances (e.g., cleaning agents), prolonged or repeated water contact, high air temperature and sweating, and psychosocial stressors [7]. Symptom expression can vary greatly between individuals and in different phases of the disease. About half of all affected individuals experience moderate to severe eczema at least intermittently [8]. Very severe forms of atopic dermatitis affect about 8% of patients. In order to adapt the therapy to the course of the disease in the best possible way, an assessment of the symptomatology including objective and subjective information is necessary. The validated measuring instruments SCORAD (Scoring Atopic Dermatitis) and EASI (Eczema Area and Severity Index) are suitable for assessing the severity and for measuring progression in clinical practice [2]. (Fig. 2). Often unbearable and persistent itching is considered particularly distressing by most patients with severe atopic dermatitis and can lead to a pruritus-scratch cycle. To capture the different dimensions of impaired quality of life, the Dermatologic Quality of Life Index (DLQI) can be used. Especially in severe forms of atopic dermatitis, topical therapy alone is often insufficient, so that systemic treatment is required. The prescription of orally or subcutaneously administered systemic agents is placed on level 4 in the still valid level scheme [2]:

  • Stage 1: Dry skin: topical basic therapy/skin care; avoidance or reduction of provoking factors.
  • Stage 2: Mild eczema: required measures of stage 1 plus antipruritic and anti-inflammatory agents; mild topical glucocorticoids and/or (from 3 years of age) topical calcineurin inhibitors.
  • Stage 3: Moderate eczema: required measures of stages 1-2 plus topical glucocorticoids (class 2 to 3) and/or (from 3 years of age) topical calcineurin inhibitors.
  • Stage 4: Persistent severe eczema: required measures of stages 1-3 plus systemic immunomodulatory therapy (tablets/injections to regulate the immune system).

 

 

 

Literature:

  1. Harb H, Chatila TA: Mechanisms of Dupilumab. Clinical & Experimental Allergy 2020; 50(1): 5-14. https://doi.org/10.1111/cea.13491
  2. AWMF: Guideline Neurodermatitis [atopic eczema; atopic dermatitis] Development stage: S2k. AWMF Register Number: 013-027 Long version, www.awmf.org
  3. Swiss Drug Compendium: Dupixent, www.compendium.ch
  4. European Medicines Agency: Dupixent. Product information, summary of product characteristics, www.ema.europa.eu
  5. Del Rosso JQ: Monoclonal Antibody Therapies for atopic dermatitis: where are we now in the spectrum of disease management? J Clin Aesthet Dermatol. 2019;12(2): 39-41.
  6. Hamilton JD, et al: Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014; 134(6): 1293-1300.
  7. Trautmann A, et al: Atopic eczema. Allergology in Clinic and Practice 2018, DOI: 10.1055/b-0037-147082, www.thieme-connect.de
  8. German Skin and Allergy Aid Association, www.dha-schwere-neurodermitis.de
  9. Gandhi NA, et al: Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2015; 15: 35-50.
  10. Noda, et al: The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 2015; 135: 324-336.

 

DERMATOLOGY PRACTICE 2020; 30(2): 28-29

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • dermatitis
Previous Article
  • Multiple sclerosis

Therapy recommendations to improve mobility impairments.

  • Education
  • Neurology
  • Prevention and health care
  • RX
  • Studies
View Post
Next Article
  • Medullary thyroid carcinoma

Calcitonin as a tumor marker

  • Education
  • Endocrinology and Diabetology
  • Oncology
  • RX
View Post
You May Also Like
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.